Helicobacter pylori
Conditions
Interventions
14-day dual regimen group:14-day dual regimen with vonoprazan (vonoprazan 20 mg bid + amoxicillin 1 g TID)
14-day quadruple therapy:14-day bismuth containing quadruple therapy (lansoprazole 30 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid + bismuth potassium citrate 600 mg bid)
Sponsors
The first affiliated hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 69 years; 2. The patients with Helicobacter pylori infection were determined to be positive by at least the following two methods: rapid urease test, histopathology, HP culture and fecal HP antigen; Or the physical examination found that 13C breath test was positive, and the DOB value close to the critical value was excluded (4 - 8‰); 3. Have not received Helicobacter pylori eradication treatment in the past; 4. Willing to carry out anti HP treatment and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to any of the tested drugs (vonoprazan fumarate and related compounds, proton pump inhibitor (PPI), clarithromycin, amoxicillin, bismuth agent or lansoprazole); 2. Partial or subtotal gastrectomy; 3. Subjects whose liver function test value is 1.5 times higher than the upper limit of normal value; 4. Those who used antibiotics or steroids within 4 weeks before enrollment and PPI or walker within 2 weeks before enrollment; 5. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 13C-UBT; | — |
Countries
China
Contacts
Public ContactLei Xiaoyi
The first affiliated hospital of Xiamen University
Outcome results
None listed